INBX

Inhibrx Biosciences, Inc.

NasdaqGSUSDEQUITY DELAYED

103.63

▲ 4.48 (4.52%)

MARKET · —

Price

Open

96.76

Prev close

99.15

Day high

105.65

Day low

99.06

Volume

220.23K

Market cap

—

P/E (TTM)

—

52W range

24.27 – 155.29

Trailing performance

Price return · vs SPY

Returnvs SPY

+17.27% +18.6%

+21.92% +18.2%

-6.28% -9.4%

+31.78% +20.7%

YTD

+31.18% +18.9%

+324.54% +304.5%

— -74.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

96.01

+7.93% from price

SMA 20

89.64

+15.60% from price

SMA 50

91.52

+13.24% from price

SMA 100

96.34

+7.57% from price

SMA 200

86.80

+19.39% from price

EMA 12

95.10

+8.97% from price

EMA 26

92.37

+12.19% from price

EMA 50

92.39

+12.16% from price

RSI (14)

63.5

Neutral

MACD (12,26,9)

2.73

Hist 1.85

ATR (14)

6.33

6.11% of price

Realised vol 30D

58.2%

Annualised

Bollinger upper

104.36

20, 2σ

Bollinger lower

74.93

20, 2σ

50 / 200 cross

Golden

91.52 vs 86.80

Trend bias

Above 200

+19.39%

Risk profile

Daily returns · 1Y window

Beta vs SPY

2.51

More volatile than market

Correlation to SPY

0.25

Largely independent

Realised vol 30D

58.2%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-44.1%

Peak to trough

Max drawdown 5Y

-44.1%

Peak to trough

ATR 14

6.33

6.11% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 103.63

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

INBX · links out to the publisher

Inhibrx Reports Second Quarter 2026 Financial Results PR Newswire · 9d ago Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million PR Newswire · 37d ago Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice Zacks · 44d ago Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR Newswire · 68d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.